Gold prices bounce off 3-week lows; demand likely longer term
Emily Leproust, the CEO of Twist Bioscience Corp (NASDAQ:TWST), recently sold a portion of her holdings in the company. According to a regulatory filing, Leproust sold 2,402 shares of common stock on March 6, 2025, at an average price of $40.913 per share. The total value of this transaction amounted to approximately $98,273. The sale occurred at a higher price than the current trading level of $36.71, with the stock showing significant volatility this year, having declined about 15% year-to-date. According to InvestingPro analysis, the stock appears to be fairly valued at current levels.
This sale was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units, as mandated by the company’s equity incentive plans. Following this transaction, Leproust retains ownership of 662,692 shares in Twist Bioscience. The company maintains a strong liquidity position with a current ratio of 4.96 and operates with moderate debt levels. InvestingPro subscribers have access to 7 additional key insights about TWST, including detailed financial health metrics and future growth projections.
In other recent news, Twist Bioscience Corporation reported financial results for the first quarter of fiscal year 2025, surpassing consensus predictions and previously issued company guidance. The company revised its full-year fiscal 2025 guidance upward, projecting total revenue growth of 19-21% year-over-year, an increase from the prior forecast of 17-20%. Gross margins are expected to be around 49% for the full year and above 50% for the fourth quarter, showing an improvement from previous estimates. Additionally, Twist Bioscience anticipates an improved adjusted EBITDA loss of about $36 million.
In corporate developments, Twist Bioscience held its Annual Meeting of Stockholders, where stockholders approved an increase in authorized common stock by an additional 100 million shares and amendments to the company’s equity incentive plan. Analyst activity has been positive, with Scotiabank (TSX:BNS) raising the company’s price target to $62 and maintaining a Sector Outperform rating, while Barclays (LON:BARC) increased its price target to $58 and reiterated an Overweight rating. Both analysts highlighted the company’s strong momentum in its SynBio and NGS segments, as well as its strategic focus on profitability and innovation. These developments reflect the company’s growth strategy and commitment to aligning employee and shareholder interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.